Thurston Springer Miller Herd & Titak Inc. Lowers Holdings in Eli Lilly and Company $LLY

Thurston Springer Miller Herd & Titak Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 96.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 722 shares of the company’s stock after selling 18,349 shares during the period. Eli Lilly and Company makes up about 1.1% of Thurston Springer Miller Herd & Titak Inc.’s holdings, making the stock its 9th largest holding. Thurston Springer Miller Herd & Titak Inc.’s holdings in Eli Lilly and Company were worth $552,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter worth $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $29,000. Steph & Co. boosted its stake in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $31,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,042.06 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a 50 day moving average price of $951.95 and a 200 day moving average price of $826.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The stock has a market capitalization of $985.14 billion, a P/E ratio of 50.98, a PEG ratio of 1.32 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. CICC Research increased their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Guggenheim reaffirmed a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Daiwa Capital Markets set a $1,230.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday. Finally, Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $1,141.73.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.